Professional Development Cafés
Join us for our first relaunched Professional Development Café!
On Friday, Dec. 8, FDA approved gene therapies Casgevy and Lyfgenia to treat sickle cell disease in patients 12 years and older. These treatments are the first gene therapies approved for SCD in the U.S. and Casgevy is the first approved therapy in the U.S. that uses CRISPR. During this café, our speakers will dive deeper into CRISPR's applications.
Who: Speaker Julian Grünewald, MD, PhD and moderator Ben Kleinstiver, PhD
What: A Professional Development Café that dives into CRISPR's applications in research and medicine.
When: December 15, 2023 from 1-2 pm CT
Where: Virtually
Why: CRISPR technology has opened up new possibilities in precision medicine and has the potential to revolutionize the treatment of many currently incurable diseases. As research progresses, we can expect more advancements and applications of this technology in the field of medicine.
Join ASGCT and Drs. Grünewald and Kleinstiver for an in-depth exploration of CRISPR applications in both research and medicine. As always, on-demand access to all past cafés is available for ASGCT members and registrants to conveniently view later. Not a member? Discover the benefits of membership today and get the remainder of 2023 FREE.
Speaker Profile: Julian Grünewald, MD, PhD
Technical University of Munich
In 2022, Dr. Grünewald joined the Technical University of Munich and the Department of Cardiology at the Klinikum rechts der Isar university hospital as a Rudolf Moessbauer fellow. The Grünewald laboratory develops CRISPR technologies for application in organoid systems and for the treatment of cardiovascular diseases.
.png)
Moderator Profile: Ben Kleinstiver, PhD
Harvard Medical School
Dr. Kleinstiver received his Ph.D in biochemistry from the University of Western Ontario, and completed his postdoctoral studies at Massachusetts General Hospital and Harvard Medical School. Within the Center for Genomic Medicine at MGH, the Kleinstiver laboratory seeks to address limitations of CRISPR genome editing technologies while solving important research questions at the forefront of the genome editing field.